Hong Kong Stocks Rebound Following More Than Expected Growth in China's Manufacturing Sector

Hong Kong stocks rebounded to start the week in green after staying in red for multiple consecutive sessions as a Caixin report showed more than expected growth in China's manufacturing sector last mo

MT NewswiresJun 3 04:43 ET

Jacobio Pharmaceuticals Presents Data on Lung Cancer Treatment at US Oncology Meet; Shares Surge 12%

Jacobio Pharmaceuticals (HKG:1167) presented the safety and efficiency data of Glecirasib, or JAB-21822, combined with JAB-3312 for frontline non-small cell lung cancer patients with a KRAS G12C mutat

MT NewswiresJun 3 03:52 ET

Changes in Hong Kong stocks | Gacos-B (01167) rose more than 11% to release SHP2 and KRAS G12C combined data MPFs for over a year

The Zhitong Finance App learned that Gacos-B (01167) rose more than 11% in the afternoon. As of press release, it had risen 9.62% to HK$1.71, with a turnover of HK$1,9392 million. According to the news, at the 2024 ASCO annual meeting, Gacos Pharmaceuticals announced the safety and efficacy data update of the combined use of Glecirasib (KRAS G12C inhibitor) and JAB-3312 (SHP2 inhibitor) in first-line non-small cell lung cancer (NSCLC) patients in the form of an oral report, and announced Glecirasib for 2 in the form of an oral report at the 2024 ASCO annual meeting

Zhitong FinanceJun 3 02:00 ET

Gacos-B (01167.HK): Presenting two clinical data in the form of an oral report at the 2024 ASCO Conference

Glonghui, June 2 | Gacos-B (01167.HK) issued an announcement. The company announced the safety and efficacy data update of Glecirasib (KRAS G12C inhibitor) and JAB3312 (SHP2 inhibitor) in combination with first-line non-small cell lung cancer (NSCLC) patients at the 2024 American Society of Clinical Oncology (ASCO) annual meeting, and announced Glecirasib in the form of an oral report in the form of an oral report on the use of Glecirasib (KRAS G12C inhibitor) and JAB3312 (SHP2 inhibitor) in combination with patients with first-line non-small cell lung cancer (NSCLC). Phase II Note for Patients with Cellular Lung Cancer

Gelonghui FinanceJun 2 06:11 ET

Jacobio Pharmaceuticals Group's Lung Cancer Drug Get NDA From China's NMPA

Jacobio Pharmaceuticals Group (HKG:1167) said its New Drug Application for its independently developed novel KRAS G12C inhibitor Glecirasib has been accepted and granted priority review designation by

MT NewswiresMay 21 23:13 ET

A new drug marketing application for the KRAS G12C inhibitor Glecirasib (JAB-21822) independently developed by Gacos-B (01167) was accepted and included in priority review

Gacos-B (01167) announced that Glecir, a KRAS G12C inhibitor independently developed by the company...

Zhitong FinanceMay 21 07:36 ET